Regeneron Pharmaceuticals engages in the research, development, manufacturing, and sale of prescription drugs. Its medications are primarily used to treat eye diseases, atopic dermatitis, asthma, and certain tumors. Additionally, the company has clinical-stage product candidates in autoimmune and cardiovascular diseases. The company relies on its proprietary genetic technologies and external corporate partnerships to advance the clinical testing and regulatory review procedures of related medical projects.